Crossmark Global Holdings Inc. Buys 535 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Crossmark Global Holdings Inc. increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 17.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,672 shares of the company’s stock after purchasing an additional 535 shares during the period. Crossmark Global Holdings Inc.’s holdings in Vaxcyte were worth $277,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Parallel Advisors LLC increased its position in shares of Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Principal Financial Group Inc. grew its position in Vaxcyte by 1.7% in the fourth quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock valued at $1,382,000 after acquiring an additional 376 shares during the last quarter. Fifth Third Bancorp bought a new position in Vaxcyte in the second quarter valued at about $35,000. J.Safra Asset Management Corp grew its position in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares during the last quarter. Finally, Fidelis Capital Partners LLC bought a new position in Vaxcyte in the first quarter valued at about $37,000. Institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PCVX shares. Needham & Company LLC lifted their target price on Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday. Leerink Partners lifted their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $131.83.

Insider Buying and Selling

In related news, SVP Mikhail Eydelman sold 1,667 shares of Vaxcyte stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.37, for a total value of $127,308.79. Following the transaction, the senior vice president now directly owns 30,826 shares of the company’s stock, valued at $2,354,181.62. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Vaxcyte news, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.37, for a total value of $127,308.79. Following the transaction, the senior vice president now directly owns 30,826 shares of the company’s stock, valued at $2,354,181.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares in the company, valued at $37,822,574.24. The disclosure for this sale can be found here. Insiders have sold a total of 70,283 shares of company stock valued at $5,613,568 over the last ninety days. 3.10% of the stock is owned by company insiders.

Vaxcyte Trading Down 0.9 %

NASDAQ:PCVX opened at $109.15 on Thursday. The stock has a market cap of $12.18 billion, a P/E ratio of -25.50 and a beta of 0.97. The stock’s 50-day moving average is $80.41 and its 200-day moving average is $73.01. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $119.27.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.12). During the same period in the prior year, the company posted ($0.70) earnings per share. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.